Invention Grant
- Patent Title: Ex vivo antibody production
-
Application No.: US16575518Application Date: 2019-09-19
-
Publication No.: US12084681B2Publication Date: 2024-09-10
- Inventor: Paula Maria Wilhelmina Van Helden , Mark Jeroen Kwakkenbos , Hergen Spits , Tim Beaumont
- Applicant: KLING BIOTHERAPEUTICS B.V.
- Applicant Address: NL Amsterdam
- Assignee: KLING BIOTHERAPEUTICS B.V.
- Current Assignee: KLING BIOTHERAPEUTICS B.V.
- Current Assignee Address: NL Amsterdam
- Agency: Saul Ewing LLP
- Agent Gianna Julian Arnold
- Priority: EP 199584 2013.12.24
- The original application number of the division: US15106991
- Main IPC: C12N5/0781
- IPC: C12N5/0781 ; A61K38/00 ; C07K16/00 ; C07K16/10 ; C12N15/06 ; C12N15/86 ; C12P21/00
Abstract:
The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
Public/Granted literature
- US20200149007A1 EX VIVO ANTIBODY PRODUCTION Public/Granted day:2020-05-14
Information query
